Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 3159       

    Article Cited by others

REVIEW ARTICLE

Fidaxomicin - the new drug for Clostridium difficile infection

Vaishnavi Chetana

Year : 2015| Volume: 141| Issue : 4 | Page no: 398-407

   This article has been cited by
 
1 Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile-Associated Infection
Mark E. Pulse,William J. Weiss,Johan A. Kers,Anthony W. DeFusco,Jae H. Park,Martin Handfield
Antimicrobial Agents and Chemotherapy. 2019; 63(4)
[Pubmed]  [Google Scholar] [DOI]
2 OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
Johan A. Kers,Anthony W. DeFusco,Jae H. Park,Jin Xu,Mark E. Pulse,William J. Weiss,Martin Handfield,Mohamed N. Seleem
PLOS ONE. 2018; 13(6): e0197467
[Pubmed]  [Google Scholar] [DOI]
3 Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection
Johan A. Kers,Robert E. Sharp,Anthony W. Defusco,Jae H. Park,Jin Xu,Mark E. Pulse,William J. Weiss,Martin Handfield
Frontiers in Microbiology. 2018; 9
[Pubmed]  [Google Scholar] [DOI]
4 ??????????? ???????????? ???????????? ?????????? ???????????? ?? ???????? ????????, ????????? ? ????????? ??????????? ??????, ? ?????????????? ???????????? ?????????????? ??????????? «?????????? ??????????????? ??????» ?? ???????????, ??????? ? ???????????? CLOSTRIDIUM DIFFICILE-??????????????? ?????? (CDI)
Yu. A. Shelygin,V. A. Aleshkin,M. A. Sukhina,A. Yu. Mironov,N. I. Briko,R. S. Kozlov,V. V. Zverev,S. I. Achkasov,O. V. Kovalishena,E. P. Selkova,A. L. Safin,T. A. Grenkova,I. L. Khalif,S. A. Frolov,V. N. Kashnikov,O. I. Sushkov
Koloproktologia. 2018; (3): 7
[Pubmed]  [Google Scholar] [DOI]
5 Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia
Martin Novotný,Pavol Jarcuška,Laura Gombošová,Ján Hockicko,Ivana Hockicková,Alena Rovnáková,Ondrej Zahornacký,Ivan Schréter,Erik Dorko,Kvetoslava Rimárová
Central European Journal of Public Health. 2018; 26(88): S76
[Pubmed]  [Google Scholar] [DOI]
6 Perspectivas históricas y vigentes sobre la infección por Clostridium difficile
D.A. Álvarez-Hernández,A.M. González-Chávez,D. González-Hermosillo-Cornejo,G.A. Franyuti-Kelly,A. Díaz-Girón-Gidi,R. Vázquez-López
Revista de Gastroenterología de México. 2017;
[Pubmed]  [Google Scholar] [DOI]
7 Present and past perspectives on Clostridium difficile infection
D.A. Álvarez-Hernández,A.M. González-Chávez,D. González-Hermosillo-Cornejo,G.A. Franyuti-Kelly,A. Díaz-Girón-Gidi,R. Vázquez-López
Revista de Gastroenterología de México (English Edition). 2017;
[Pubmed]  [Google Scholar] [DOI]
8 Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin
Cláudia Gomes,Sandra Martínez-Puchol,Noemí Palma,Gertrudis Horna,Lidia Ruiz-Roldán,Maria J Pons,Joaquim Ruiz
Critical Reviews in Microbiology. 2017; 43(1): 1
[Pubmed]  [Google Scholar] [DOI]
9 Clostridium Difficile Infection in Children
Elena Borali,Costantino De Giacomo
Journal of Pediatric Gastroenterology and Nutrition. 2016; 63(6): e130
[Pubmed]  [Google Scholar] [DOI]

 

Read this article